Heart failure & cardiomyopathies
A hierarchical kidney outcome using win statistics in patients with heart failure from the DAPA-HF and DELIVER trials
Authors' conclusion
For this outcome, the win ratio was 1.10 (95% confidence interval (CI) = 1.06-1.15) in the combined dataset, 1.08 (95% CI = 1.01-1.16) in the DAPA-HF trial and 1.12 (95% CI = 1.05-1.18) in the DELIVER trial; that is, dapagliflozin was superior to placebo in both trials.
Study context
- Population
- Patients with HF with reduced (DAPA-HF) or mildly reduced or preserved EF (DELIVER)
- Comparison
- Dapagliflozin vs placebo
- Primary endpoint
- Hierarchical composite kidney outcome:
- All-cause mortality
- End-stage kidney disease
- Estimated glomerular filtration rate (eGFR) decline ≥57%
- eGFR decline ≥50%
- eGFR decline ≥40%
- Participant-level eGFR slope
Methodological detailswin statistics
- Win statistics
Primary result
As reported in the abstract
Hierarchical composite kidney outcome
Dapagliflozin vs PlaceboWin ratio (95% CI)
Combined dataset
1.10(1.06–1.15)
DAPA-HF
1.08(1.01–1.16)
DELIVER
1.12(1.05–1.18)
Further findings
Hierarchical kidney outcome, by baseline kidney disease and T2DM (subgroups)
- Benefits consistent with and without baseline kidney disease, and with and without T2DM
Original publication
A hierarchical kidney outcome using win statistics in patients with heart failure from the DAPA-HF and DELIVER trials. Nat Med. Published 6 May 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →